Hims & Hers Health (NYSE:HIMS) Given New $40.00 Price Target at Morgan Stanley

Hims & Hers Health (NYSE:HIMS) had its price objective trimmed by Morgan Stanley from $60.00 to $40.00 in a research report released on Tuesday,Benzinga reports. The firm currently has an equal weight rating on the stock.

HIMS has been the subject of a number of other research reports. Bank of America upped their target price on Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a report on Tuesday, March 18th. TD Cowen lowered shares of Hims & Hers Health from a “buy” rating to a “hold” rating and dropped their price objective for the company from $44.00 to $30.00 in a report on Tuesday. Needham & Company LLC boosted their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th. Citigroup dropped their price target on shares of Hims & Hers Health from $27.00 to $25.00 and set a “sell” rating for the company in a research note on Friday, April 25th. Finally, Truist Financial reduced their price objective on shares of Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating on the stock in a research note on Thursday, April 10th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $36.92.

Hims & Hers Health Trading Up 23.2 %

Shares of NYSE HIMS opened at $35.08 on Tuesday. The company has a market cap of $7.79 billion, a price-to-earnings ratio of 79.73 and a beta of 1.65. Hims & Hers Health has a 12 month low of $11.20 and a 12 month high of $72.98. The stock has a 50-day moving average price of $32.81 and a two-hundred day moving average price of $31.18.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, sell-side analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current year.

Insider Buying and Selling

In other Hims & Hers Health news, COO Melissa Baird sold 33,333 shares of the firm’s stock in a transaction on Monday, April 21st. The shares were sold at an average price of $25.78, for a total value of $859,324.74. Following the completion of the sale, the chief operating officer now directly owns 805,083 shares in the company, valued at approximately $20,755,039.74. This trade represents a 3.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Irene Becklund sold 2,936 shares of the company’s stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $26.49, for a total transaction of $77,774.64. Following the transaction, the insider now owns 5,071 shares in the company, valued at $134,330.79. This represents a 36.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 712,998 shares of company stock valued at $27,992,450 over the last 90 days. Company insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Large investors have recently made changes to their positions in the company. SlateStone Wealth LLC boosted its holdings in Hims & Hers Health by 4.0% in the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock worth $257,000 after acquiring an additional 413 shares in the last quarter. Blume Capital Management Inc. raised its position in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares during the period. Summit Investment Advisors Inc. lifted its holdings in shares of Hims & Hers Health by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock worth $480,000 after purchasing an additional 628 shares in the last quarter. Cim LLC lifted its holdings in shares of Hims & Hers Health by 1.0% in the 4th quarter. Cim LLC now owns 71,869 shares of the company’s stock worth $1,738,000 after purchasing an additional 694 shares in the last quarter. Finally, Harbour Investments Inc. grew its position in Hims & Hers Health by 18.8% in the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock valued at $127,000 after purchasing an additional 833 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.